AMDX 2011P
Alternative Names: Alpha synucleinopathies targeted small molecule retinal tracer; AMDX-2011-P; AMDXP-2011-P; TAR DNA binding protein 43 targeted small molecule retinal tracerLatest Information Update: 29 Jul 2024
At a glance
- Originator Amydis
- Developer Amydis; University of California, San Diego
- Class Contrast media; Diagnostic agents; Small molecules
- Mechanism of Action Diagnostic imaging enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Alzheimer's disease; Cerebral amyloid angiopathy; Open-angle glaucoma
- Phase I Amyotrophic lateral sclerosis; Parkinson's disease
- Research Neurodegenerative disorders
Most Recent Events
- 25 Jul 2024 Phase-II clinical trials in Alzheimer's disease (Diagnosis) in USA (IV) (NCT06514001)
- 01 Mar 2024 Phase-II clinical trials in Cerebral amyloid angiopathy (Diagnosis) in USA (IV) (NCT05709314)
- 02 Feb 2023 Amydis in collaboration with National Institutes of Health plans a phase I/II trial for Cerebral amyloid angiopathy (In adults, In the elderly) in USA (IV) in February 2023 (NCT05709314)